NCT00399048View on ClinicalTrials.gov

An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

PHASE3CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 2001

Conditions

Osteoarthritis, KneeOsteoarthritis, Hip

Interventions

DRUG

OROS hydromorphone HCL ; OxyContin

All Listed Sponsors

lead

Alza Corporation, DE, USA

INDUSTRY